Details the harmful impacts copay accumulators have on drug adherence and patients costs, federal and state actions taken to date to ensure copay assistance counts, and advocacy opportunities at the federal and state levels patient groups can engage in relative to copay accumulators.
Carl Schmid and Frank J. Palella, MD, discuss how coverage differs for medications vs ancillary service costs for HIV PrEP based on USPSTF guidelines.
Carl Schmid discusses the implications of the USPSTF Grade A rating of HIV PrEP to patients, providers, and payers.
This multi-stakeholder roundtable panel discussion will focus on how to address barriers and disparities as obstacles to the use of PrEP, with a focus on increased understanding and education around US Preventive Services Task Force (USPSTF) PrEP guidelines and Affordable Care Act Part 47 for payers and providers.
Examines how insurance benefit design, including high deductibles and co-insurance, impact prescription drug access, along with the importance of copay assistance and how states are ensuring that it count towards beneficiary cost-sharing obligations.